Claims for Patent: 9,308,204

Summary for Patent: 9,308,204

Title:	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Abstract:	Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001##
Inventor(s):	Mascitti; Vincent (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/535,630
Patent Claims:	1. A pharmaceutical composition comprising: (i) (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (ii) a pharmaceutically acceptable excipient, diluent, or carrier; and (iii) sitagliptin. 2. A pharmaceutical composition comprising: (i) (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (ii) a pharmaceutically acceptable excipient, diluent, or carrier; and (iii) metformin. 3. The composition of claim 1 wherein (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol is present in a therapeutically effective amount. 4. The composition of claim 2 wherein (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol is present in a therapeutically effective amount.